Skip to main content

VERACYTE INC

For the period ended Dec 31, 2024. Filed Feb 28, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 28, 2025

VCYT$24.06-7.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits, Financial Statement Schedules

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)Documents filed as part of this report

  1. Financial Statements:

Reference is made to the Financial Statements and Supplementary Data included in Item 8 of Part II hereof.

  1. Financial Statement Schedules

All schedules have been omitted because they are not required, not applicable, or the required information is included in the financial statements or notes thereto.

  1. Exhibits

A list of exhibits to this Annual Report on Form 10-K is set forth below and is incorporated herein by reference. See Item 15(b) below. Each management contract or compensating plan or arrangement required to be filed has been identified.

(b)Exhibits

Incorporated by Reference
Exhibit NumberDescriptionFormFile No.ExhibitFiling DateFiled Herewith
3.1Restated Certificate of Incorporation of the Registrant8-K001-361563.26/9/2023
3.2Amended and Restated Bylaws of the Registrant8-K001-361563.36/9/2023
4.1Form of Common Stock CertificateS-1/A333-1912824.110/15/2013
4.2Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934, as amendedX
10.1#Form of Indemnification Agreement between the Registrant and its officers and directorsS-1/A333-19128210.110/7/2013
10.2#2013 Stock Incentive Plan, as amended, and forms of stock option award agreement, stock option exercise agreement, restricted stock agreement and restricted stock unit agreement8-K001-3615610.13/3/2021
10.3#Form of stock option award under 2013 Stock Incentive Plan10-Q001-3615610.111/2/2020
10.4#Form of stock unit award under 2013 Stock Incentive Plan10-Q001-3615610.111/2/2020
10.5#Amended and Restated Employee Stock Purchase Plan10-Q001-3615610.17/30/2020
10.6#Form of Performance Stock Unit10-Q001-3615610.15/1/2018
10.7†License and Asset Purchase Agreement, dated December 3, 2019, between NanoString Technologies, Inc. and the Registrant8-K001-361562.112/3/2019
Incorporated by Reference
Exhibit NumberDescriptionFormFile No.ExhibitFiling DateFiled Herewith
10.8#Employment Agreement, dated as of May 7, 2021, between Marc Stapley and the Registrant10-Q001-3615610.27/29/2021
10.9#Change in Control and Severance Agreement, effective June 1, 2021 between Marc Stapley and the Registrant10-Q001-3615610.37/29/2021
10.10#Amended and Restated Offer Letter, dated August 15, 2021, between the Registrant and Rebecca Chambers10-Q001-3615610.111/9/2021
10.11#Change in Control and Severance Agreement, effective July 19, 2021 between Rebecca Chambers and the Registrant10-Q001-3615610.211/9/2021
10.12#Offer Letter, dated as of January 9, 2023, between Annie McGuire and the Registrant10-K001-3615610.323/1/2023
10.13#Change of Control and Severance Agreement, effective January 1, 2023, between Annie McGuire and the Registrant10-K001-3615610.333/1/2023
10.14#2023 Equity Incentive Plan, as amended8-K001-3615610.16/13/2024
10.15#Form of agreements under the 2023 Equity Incentive Plan8-K001-3615610.26/9/2023
10.16#Promotion Letter, dated as of August 22, 2023, between John Leite and the Registrant10-K001-3615610.232/29/2024
10.17#Change of Control and Severance Agreement, effective September 1, 2023, between John Leite and the Registrant10-K001-3615610.242/29/2024
10.18#Offer Letter, dated as of September 11, 2023, between Phil Febbo and the Registrant10-K001-3615610.252/29/2024
10.19#Change of Control and Severance Agreement, effective October 2, 2023, between Phil Febbo and the Registrant10-K001-3615610.262/29/2024
10.20#2019 Stock Incentive Plan of C2i Genomics, Inc.10-K001-3615610.272/29/2024
10.21#Form of Option Grant under the 2019 Stock Incentive Plan of C2i Genomics, Inc.10-K001-3615610.282/29/2024
10.22#Form of Stock Option Assumption Notice by the Registrant to Option holders of C2i Genomics, Inc.10-K001-3615610.292/29/2024
19.Insider Trading PolicyX
21.1List of SubsidiariesX
23.1Consent of Independent Registered Public Accounting FirmX
31.1Principal Executive Officer’s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
31.2Principal Financial Officer’s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
Incorporated by Reference
Exhibit NumberDescriptionFormFile No.ExhibitFiling DateFiled Herewith
32.1* · Certification Pursuant to 18 U.S.C. § 1350 (Section 906 of the Sarbanes-Oxley Act of 2002) · X
32.2* · Certification Pursuant to 18 U.S.C. § 1350 (Section 906 of the Sarbanes-Oxley Act of 2002) · X
97.1Compensation Recovery Policy10-K001-3615697.12/29/2024
101.INSInline XBRL Instance DocumentX
101.SCHInline XBRL Taxonomy Extension SchemaX
101.CALInline XBRL Taxonomy Extension Calculation LinkbaseX
101.DEFInline XBRL Taxonomy Extension Definition LinkbaseX
101.LABInline XBRL Taxonomy Extension Label LinkbaseX
101.PREInline XBRL Taxonomy Extension Presentation LinkbaseX
104Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101)X
#Indicates management contract or compensatory plan or arrangement.
*In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the registrant specifically incorporates it by reference.
†Registrant is requesting or has previously been granted confidential treatment with respect to certain portions of this Exhibit.

Copies of the above exhibits not contained herein are available to any stockholder, upon payment of a reasonable per page fee, upon written request to: Chief Financial Officer, Veracyte, Inc., 6000 Shoreline Court, Suite 300, South San Francisco, California 94080.

(c)Financial Statement Schedules

Reference is made to Item 15(a) 2 above.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.